@JMAC_454 @AlastairMcA30 @Ricey709 @ScottAdamsSays It is true though, we know when you are infected with a strain, you are protected primarily from that strain. The same is true for vaccination. https://t.co/Kx8aLaInea
@harald_erler @JimJamLFC @EricTopol @PLOSBiology @Prof_LDHurst @AnneF_S The vaccines were 95% effective at preventing symptomatic infection against the initial strain. They declined to about 60% vs. the same against omicron and its sublineages. The bivalen
@MarcSchaefferGD @matthewherper @Bob_Wachter @HelenBranswell efficacy PEAKED at 20-50% for the bivalent, while BA.5 was still circulating. boosting to prevent infection just isn't going to work. maybe if you get boosted once a month https://t.co/pCJxcJZa0d
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what? This means they PRE…
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what? This means they PRE…
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what? This means they PREVENTED COVID. •https://t.co/RhsS2M2FZj
#ワクチン複数回接種は有害の可能性大 感染予防効果 ほぼ無し 自然免疫生成の邪魔な 有害化の可能性大 >Relative vaccine effectiveness dose was 28% and 43% https://t.co/AXntQNOaHU
RT @influenzer3: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Te…
RT @hfrank6048: @A352427 @tommyboy0690 https://t.co/DeCLpkby5b “bivalent boosters provided significant additional protection against sympt…
RT @hfrank6048: @A352427 @tommyboy0690 https://t.co/DeCLpkby5b “bivalent boosters provided significant additional protection against sympt…
RT @hfrank6048: @A352427 @tommyboy0690 https://t.co/DeCLpkby5b “bivalent boosters provided significant additional protection against sympt…
@A352427 @tommyboy0690 https://t.co/DeCLpkby5b “bivalent boosters provided significant additional protection against symptomatic SARS-CoV-2 infection in persons who had previously received 2, 3, or 4 monovalent vaccine doses.” DeSantis is not only wrong.
@NathanSteiner @timmullaney @FLVoiceNews Here's one specifically on the bivalent vaccine. They found it wasn't highly effective, but it was effective, especially if it had been a long time since your last dose. https://t.co/Oc7bCS7baz https://t.co/1MC9sJ
Tam sözünü ettiğiniz türden değerlendirme değil ama yine de anlamlı: This study evaluated aVE and rVE by number of previous monovalent doses received and generally found similar additional benefit of the bivalent vaccine ... https://t.co/TG6irl2HXF
@GovRonDeSantis Idiots with no scientific expertise need to shut up about vaccines. You need to pay attention to the scientists and medical experts. https://t.co/THcbWEeX8b
@HidingoutinFL @TheBoyConker @DrCanuckMD There has been ONE bivalent vax study since Sept release. You've stated some common hearsay misinfo that's inconsistent w/ the report's findings & CDC's announcements Effectiveness of Bivalent mRNA Vaccines in
RT @carpe_diem0820: 米国での2価ワクチンの有効性報告 前回接種からの間隔の長期化で有効性↑ 重症化予防約50% Effectiveness of Bivalent mRNA Vaccines in Preventing COVID-19-Associate…
RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると ・武漢株💉2回:-26% ・武漢株💉3回:-59% ・武漢株💉4回:-76% となって、💉するほど非接種者より感染しやす…
@TheSadViolin @jumpstart1977 @mountain_ted @healthbyjames Again, let me know if the words are too big for you… https://t.co/81Mt7lA08u
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst…
@uppercasemag @EricTopol @CorsIAQ @NEJM It does stop transmission https://t.co/Drc3MZpwuZ
@joindontdie @coloradobenji It was dumb of you to think that prevents transmission meant 100% of all infections all the time. https://t.co/Drc3MZpwuZ
@BridgetVervain @flarfernutter @joindontdie They prevent transmission, just not 100% https://t.co/Drc3MZpwuZ
@joindontdie The covid vaccines do prevent transmission. https://t.co/Drc3MZpwuZ
@jbart1055 @richardzussman Bivalent vaccine is ineffective - way under 50% protection: https://t.co/p3QP8Zyl5Y
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR https://t.co/z7d2tkxWlQ
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst…
@bdonedone @chrislhayes The actual data shows the opposite. https://t.co/DBc2PpypIZ (Summary of above) https://t.co/11TNjj7UkI
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR https://t.co/eDxFZDG1cq
@DrPaulOffit so you‘re having an opinion while evidence points in a different direction? how original and smart. not. https://t.co/OHUWBUh2lS
@RepThomasMassie No vaccine is 100% effective. https://t.co/dTktFmTh6M via @CDCgov
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst…
RT @DruvBhagavan: @luckytran Per a CDC MMWR (12/2/22), the bivalent boosters offer an additional *~30-60%* protection against symptomatic i…
@MeetsLight Tässä kyseinen tutkimus. https://t.co/OE9ioKgr7e Ja tässä selitetty englanniksi: https://t.co/xC4V6nBjr4
@FellaFala @MeetsLight Löytyi useita. Katsomatta mm. Israelin data ja @DrEricDing https://t.co/AHvz4yRrY1
RT @nathan_a_tanner: @joshtpm (it is extremely clear that it helps FWIW) https://t.co/Evs24yJrBR
@joshtpm (it is extremely clear that it helps FWIW) https://t.co/Evs24yJrBR
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst…
@AtomsksSanakan @Brkr_Morant @EmilyPetro22 @Covid19Ls @mauveTriforce @zipsmooch @BogusBones208 @LobotomizedM1 @GYamey @InCytometry @MaryanneDemasi @JonathanSarfat1 Emily needs to see this thread:
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst…
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst…
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst…
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst…
@MeetsLight @Jussi7 Se on tämä toinen tutkimus https://t.co/nEyEt8PSqf
RT @Neoavatara: @KevinWGlass CONCLUSION: No discernable differences in protection against symptomatic BA.1 and BA.2 infection were seen wi…
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst…
The bivalent mRNA vaccines prevented symptomatic SARS-CoV-2 infection. PREVENTED! https://t.co/LkhwVUuPPY https://t.co/LkhwVUuPPY
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what that means? Psst. It means they PREVENTED COVID. •https://t.co/RhsS2M3dOR
@MeetsLight Toiset 5 sek käytetty. https://t.co/nEyEt8PSqf
RT @Neoavatara: @KevinWGlass CONCLUSION: No discernable differences in protection against symptomatic BA.1 and BA.2 infection were seen wi…
@KevinWGlass Nobody, including the CDC, is showing 50% efficacy after three months. At 2-3 months? Sure. https://t.co/BKfFTZ0M5f
@KevinWGlass CONCLUSION: No discernable differences in protection against symptomatic BA.1 and BA.2 infection were seen with previous infection, vaccination, and hybrid immunity. There are more studies that show this result...here is another from CDC:
@JLPJLP2k He's 100% wrong. More booster less risk of contacting COVID 19. This has been proven. He's looking at total numbers. Over 90% of the population has now had at least 1 shot. https://t.co/RY3zd8edRx
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what? This means the vacc…
RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what? This means the vacc…
RT @BOOSTICStudy: Interesting study from the @CDCgov on vaccine efficacy of bivalent mRNA COVID vaccines https://t.co/bDS5XqkIP4.
RT @BOOSTICStudy: Interesting study from the @CDCgov on vaccine efficacy of bivalent mRNA COVID vaccines https://t.co/bDS5XqkIP4.
Interesting study from the @CDCgov on vaccine efficacy of bivalent mRNA COVID vaccines https://t.co/bDS5XqkIP4.
@M_Alazon @UltimeBouts @france_soir CDC Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 https://t.co/ObEVu7H3n0
RT @DruvBhagavan: @luckytran Per a CDC MMWR (12/2/22), the bivalent boosters offer an additional *~30-60%* protection against symptomatic i…
@luckytran Per a CDC MMWR (12/2/22), the bivalent boosters offer an additional *~30-60%* protection against symptomatic infection over ≥2 monovalent only doses (rVE). Efficacy increases with time since last monovalent dose (as one might expect, given ↓ NA
@21BlackHearts @StanCat10338832 @MattWallace888 I’m a “medical professional”. I’ve been a nurse for over 40 years. I’m fully vaccinated (5 vaccines) and I believe they help mitigate symptoms but they do NOTHING for prevention. Even the CDC states this yet
RT @kakeashi_ashika: BA.5用ブースターによる中和活性評価が出揃ったところで過ぎ去りしBA.5の波に対する効果をみていく。 まずは感染防止の観点から。2022年11月22日に出たCDCのMMWR。2/3/4dosesは事前の武漢型用の接種回数だが、回数を…
RT @kakeashi_ashika: BA.5用ブースターによる中和活性評価が出揃ったところで過ぎ去りしBA.5の波に対する効果をみていく。 まずは感染防止の観点から。2022年11月22日に出たCDCのMMWR。2/3/4dosesは事前の武漢型用の接種回数だが、回数を…
RT @kakeashi_ashika: BA.5用ブースターによる中和活性評価が出揃ったところで過ぎ去りしBA.5の波に対する効果をみていく。 まずは感染防止の観点から。2022年11月22日に出たCDCのMMWR。2/3/4dosesは事前の武漢型用の接種回数だが、回数を…
RT @kakeashi_ashika: BA.5用ブースターによる中和活性評価が出揃ったところで過ぎ去りしBA.5の波に対する効果をみていく。 まずは感染防止の観点から。2022年11月22日に出たCDCのMMWR。2/3/4dosesは事前の武漢型用の接種回数だが、回数を…
BA.5用ブースターによる中和活性評価が出揃ったところで過ぎ去りしBA.5の波に対する効果をみていく。 まずは感染防止の観点から。2022年11月22日に出たCDCのMMWR。2/3/4dosesは事前の武漢型用の接種回数だが、回数を重ねるとむしろ逆効果?!BA.5用の有症状感染防止効果は50歳未満で4割、以上で2割。
@Elle_Ham06 @tedtalksoph @Otto_English @d415y4g3 "All persons should stay up to date with recommended COVID-19 vaccines, including bivalent booster doses, if it has been ≥2 months since their last monovalent vaccine dose (1)." https://t.co/XzZwVpZOMj
@DrTomFrieden why do so many believe "there has not been testing of bivalent vaccine effectiveness?" (or the claim "only 8 people tested?") The data is widely available, This is study of 360,000. I think CDC has a hard time competing with internet rumors.
@MozarkMike @DrTomFrieden 360,000 tests in the study, show bivalent is effective at reducing risk of severe CV. https://t.co/93VSnaSc1K.
RT @MarchalOmbre_: En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, mer…
RT @MarchalOmbre_: En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, mer…
RT @MarchalOmbre_: En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, mer…
RT @MarchalOmbre_: En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, mer…
RT @TracyBethHoeg: Oh boy. @CDCgov released data on the new bivalent booster & it doesn't look good at 2-3 months. They used test negative…
RT @MarchalOmbre_: En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, mer…
RT @MarchalOmbre_: En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, mer…
RT @MarchalOmbre_: En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, mer…
RT @MarchalOmbre_: En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, mer…
RT @MarchalOmbre_: En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, mer…
En novembre le CDC estimait à 20-30% la protection du bivalent à 3 mois pour les +65 ans, les plus jeunes davantage, merci à l'immunité naturelle plutôt.. sans compter qu'une étude de NATURE indique qu'il est quasiment inefficace sur les nouveaux variants
@TennisPuneet they are completely outdated, and the bivalent is about 20% of protection, likely 0 on the last variant as XBB.. BA.7 .. https://t.co/Sx1qpMNKfY
RT @carpe_diem0820: オミクロンを含む2価mRNACOVID-19ブースター接種の効果は、過去に2、3、4回の従来ワクチンを接種者でも、追加的症候性感染予防効果をもたらす Effectiveness of Bivalent mRNA Vaccines in…
RT @carpe_diem0820: オミクロンを含む2価mRNACOVID-19ブースター接種の効果は、過去に2、3、4回の従来ワクチンを接種者でも、追加的症候性感染予防効果をもたらす Effectiveness of Bivalent mRNA Vaccines in…
Su única fuente para estimar el desenlace de infección sintomática es este informe de los CDC de EEUU: https://t.co/SWsbBDcjJc
RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると ・武漢株💉2回:-26% ・武漢株💉3回:-59% ・武漢株💉4回:-76% となって、💉するほど非接種者より感染しやす…
RT @ENirenberg: No, this claim is disinformation actually. We now have epidemiological evidence that bivalent boosters enhance protection a…
RT @ENirenberg: No, this claim is disinformation actually. We now have epidemiological evidence that bivalent boosters enhance protection a…
RT @ENirenberg: No, this claim is disinformation actually. We now have epidemiological evidence that bivalent boosters enhance protection a…
RT @ENirenberg: No, this claim is disinformation actually. We now have epidemiological evidence that bivalent boosters enhance protection a…
RT @ENirenberg: No, this claim is disinformation actually. We now have epidemiological evidence that bivalent boosters enhance protection a…
No, this claim is disinformation actually. We now have epidemiological evidence that bivalent boosters enhance protection against novel Omicron subvariants. https://t.co/7rhfiYw4yI https://t.co/gryGnRiequ https://t.co/nx6Ehyy9Fa
@nancydoylebrown Antibody level changes can be cleanly measured in randomized blinded control trials. At this stage in a virus’ spread, efficacy is both harder to measure cleanly, and takes longer to determine. It has, however, also been reported. https: